# Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer

> **NCT01961544** · PHASE4 · COMPLETED · sponsor: **Eisai Korea Inc.** · enrollment: 101 (actual)

## Conditions studied

- Breast Neoplasms
- Breast Cancer

## Interventions

- **DRUG:** Eribulin mesylate

## Key facts

- **NCT ID:** NCT01961544
- **Lead sponsor:** Eisai Korea Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2016-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01961544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01961544, "Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01961544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*